mRNA vaccines

US Health Secretary Robert F. Kennedy Jr. has canceled approximately $500 million in grants and contracts for the development of mRNA vaccines, a decision that has been met with dismay from researchers and public health experts. The terminated projects, funded through the Biomedical Advanced Research and Development Authority (BARDA), were focused on creating vaccines for infectious diseases such as COVID-19, flu, and bird flu.

The Rationale and Technology

The official reason provided for the cancellation is that mRNA technology “poses more risks than benefits for these respiratory viruses” and that a single mutation can render them ineffective. The health secretary stated that the funds would be redirected to “safer, broader vaccine platforms” that are more resilient to viral mutations.

• How mRNA Vaccines Work: Unlike traditional vaccines that use weakened or inactive viruses, mRNA vaccines use a molecule called messenger RNA (mRNA) to instruct cells to produce a specific viral protein. This protein is harmless on its own, but it triggers an immune response, causing the body to produce protective antibodies. It is important to note that mRNA from vaccines does not enter the cell’s nucleus and does not alter DNA.
• Key Advantage: A major benefit of mRNA technology is its speed and adaptability. Researchers can develop and modify these vaccines in a matter of months, allowing for a rapid response to new pandemics or emerging viral variants, a capability that traditional vaccine production methods lack.